MediWound Ltd (M8W) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MediWound Ltd (M8W) has a cash flow conversion efficiency ratio of -0.069x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.02 Million ≈ $-3.53 Million USD) by net assets (€43.63 Million ≈ $51.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MediWound Ltd stock valuation for the company's overall valuation and market capitalisation.
MediWound Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how MediWound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MediWound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MediWound Ltd ranked by their cash flow conversion efficiency. Explore M8W cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Frauenthal Holding AG
VI:FKA
|
-0.048x |
|
Takkt AG
XETRA:TTK
|
0.016x |
|
Siljansvik AB (publ)
ST:SIVI
|
0.023x |
|
Hostelworld Group PLC
IR:HSW
|
0.075x |
|
Mayfield Group Holdings Ltd
AU:MYG
|
0.339x |
|
Texas Ventures Acquisition IV Corp Class A Ordinary Shares
NASDAQ:TVIV
|
-0.001x |
|
Finwise Bancorp
NASDAQ:FINW
|
0.018x |
|
Ha Tien 1 Cement JSC
VN:HT1
|
0.062x |
Annual Cash Flow Conversion Efficiency for MediWound Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of MediWound Ltd from 2016 to 2025. View M8W stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €43.63 Million ≈ $51.01 Million |
€-16.12 Million ≈ $-18.85 Million |
-0.369x | +15.51% |
| 2024-12-31 | €31.15 Million ≈ $36.42 Million |
€-13.62 Million ≈ $-15.93 Million |
-0.437x | -32.03% |
| 2023-12-31 | €31.59 Million ≈ $36.94 Million |
€-10.46 Million ≈ $-12.23 Million |
-0.331x | +69.58% |
| 2022-12-31 | €10.91 Million ≈ $12.76 Million |
€-11.88 Million ≈ $-13.89 Million |
-1.089x | -155.96% |
| 2021-12-31 | €-4.58 Million ≈ $-5.36 Million |
€-8.92 Million ≈ $-10.42 Million |
1.946x | +305.23% |
| 2020-12-31 | €7.27 Million ≈ $8.50 Million |
€-6.89 Million ≈ $-8.06 Million |
-0.948x | -273.51% |
| 2019-12-31 | €15.17 Million ≈ $17.73 Million |
€8.29 Million ≈ $9.69 Million |
0.546x | +140.34% |
| 2018-12-31 | €8.97 Million ≈ $10.49 Million |
€-12.15 Million ≈ $-14.21 Million |
-1.355x | +20.80% |
| 2017-12-31 | €9.62 Million ≈ $11.25 Million |
€-16.45 Million ≈ $-19.24 Million |
-1.710x | +19.18% |
| 2016-12-31 | €7.77 Million ≈ $9.08 Million |
€-16.45 Million ≈ $-19.23 Million |
-2.116x | -- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn cen… Read more